explore -WSS

explore

author：explore 2025-10-01 21:37:38 - browse：3

Illustration: Alex Hogan/STAT; Photo: Courtesy Perrigo

It’s not every day that a marketing team is tasked with designing the branding and packaging of the first over-the-counter birth control pill to be sold in the U.S.

This was the challenge, and the opportunity, faced by the team behind Opill, the landmark pill from drugmaker Perrigo that received approval from the Food and Drug Administration earlier this month. Their brief: Create a design that would stand out in America’s notoriously sprawling pharmacy aisles; inspire trust and confidence; be easy to remember and recognize; appeal to women — including teenagers — as well as trans men and nonbinary people; clearly communicate its purpose; be simple to carry and use; contain straightforward but accurate user information; and clear FDA requirements.

Settling on the right approach took years of research and testing, which resulted in the name Opill and packaging featuring bright teal, saturated pink, and yellow, as well as a rounded font reminiscent of millennials’ ubiquitous favorite Gotham. All of these features are intended to set the product apart from the dozens of prescription contraceptive pills available in the U.S. market and internationally.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： What don’t we know about an Alzheimer’s drug side effect?

knowledge

WSS

Medicare threatens to cut off funding for HCA's Mission hospital

The dental labor crisis is a moment of opportunity

How digital tools helped lower hypertension in marginalized patients

What we’ve learned from the Aduhelm mess

Disappointing trial forces Pfizer to pivot on obesity medicine plans

BioAge raises $170M for combination therapy with Zepbound

Wikipedia

explore

entertainment

Jerome Adams on the need for new antivirals for Covid

Takeda, Janssen join wearable maker to measure scratching

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Senators start work on Medicare physician payment reform

Bright Health sells Medicare Advantage business to Molina

A disappointing year of Humira biosimilars

Drug repurposing or repositioning? The language matters

BioAge raises $170M for combination therapy with Zepbound

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Flagship Pioneering launches a new biotech in two countries

entertainment

Private equity deals in Medicare Advantage declines

The EPA's new lead rule: How one expert crunched the numbers

Robert F. Kennedy is pitching centrism on health, even on abortion

Medicare Advantage proposed rates disappoint insurers

PhRMA lawsuit over Medicare drug price negotiation tossed

Biogen Alzheimer’s drug launch off to slow start

focus

knowledge

hotspot

Wikipedia